MA33471B1 - Formulation sous-cutanée d'anticorps anti-her2 - Google Patents

Formulation sous-cutanée d'anticorps anti-her2

Info

Publication number
MA33471B1
MA33471B1 MA34587A MA34587A MA33471B1 MA 33471 B1 MA33471 B1 MA 33471B1 MA 34587 A MA34587 A MA 34587A MA 34587 A MA34587 A MA 34587A MA 33471 B1 MA33471 B1 MA 33471B1
Authority
MA
Morocco
Prior art keywords
formulations
relates
mixture
effective amount
formulation
Prior art date
Application number
MA34587A
Other languages
Arabic (ar)
English (en)
Inventor
Michael Adler
Ulla Grauschopf
Hanns-Christian Mahler
Oliver Boris Stauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43500473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33471(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33471B1 publication Critical patent/MA33471B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique stable hautement concentrée d'un anticorps anti-HER2 pharmaceutiquement actif, tel que par exemple le Trastuzumab (HERCEPIN"), le Pertuzumab ou le T-DM1, ou un mélange de telles molécules d'anticorps destinées à être injectées de manière sous-cutanée. En particulier, la présente invention concerne des formulations comprenant, en plus d'une quantité appropriée de l'anticorps anti-HER2, une quantité efficace d'au moins une enzyme hyaluronidase sous la forme d'une formulation combinée ou destinées à être utilisées sous la forme d'une co-formulation. Lesdites formulations comprenant de plus au moins un agent tampon, tel que par exemple un tampon histidine, un agent stabilisant ou un mélange de deux ou plusieurs stabilisants (par exemple un glucide, tel que par exemple le dihydrate de ±,±-tréhalose ou le sucrose, et éventuellement de la méthionine comme second agent stabilisant), un tensioactif non ionique et une quantité efficace d'au moins une enzyme hyaluronidase. L'invention concerne également des procédés de préparation de telles formulations et leurs utilisations.
MA34587A 2009-07-31 2010-07-28 Formulation sous-cutanée d'anticorps anti-her2 MA33471B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09167025 2009-07-31
PCT/EP2010/060930 WO2011012637A2 (fr) 2009-07-31 2010-07-28 Formulation sous-cutanée d'anticorps anti-her2

Publications (1)

Publication Number Publication Date
MA33471B1 true MA33471B1 (fr) 2012-07-03

Family

ID=43500473

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34587A MA33471B1 (fr) 2009-07-31 2010-07-28 Formulation sous-cutanée d'anticorps anti-her2

Country Status (41)

Country Link
US (9) US9345661B2 (fr)
EP (4) EP4339212B1 (fr)
JP (2) JP5462944B2 (fr)
KR (2) KR101413947B1 (fr)
CN (3) CN105168125A (fr)
AR (2) AR077605A1 (fr)
AU (1) AU2010277657B2 (fr)
BR (1) BR112012002080A2 (fr)
CA (1) CA2768458C (fr)
CL (2) CL2012000269A1 (fr)
CO (1) CO6430421A2 (fr)
CR (1) CR20110679A (fr)
CY (1) CY1114185T1 (fr)
DK (3) DK2687202T3 (fr)
DO (1) DOP2015000255A (fr)
EA (2) EA031013B1 (fr)
EC (2) ECSP12011643A (fr)
ES (2) ES2948033T3 (fr)
FI (1) FI2687202T3 (fr)
GT (1) GT201200024A (fr)
HK (1) HK1215157A1 (fr)
HR (2) HRP20230462T1 (fr)
HU (1) HUE062122T2 (fr)
IL (2) IL217382A (fr)
IN (1) IN2012CN00961A (fr)
LT (1) LT2687202T (fr)
MA (1) MA33471B1 (fr)
MX (2) MX2012001124A (fr)
MY (2) MY163001A (fr)
NZ (2) NZ603900A (fr)
PE (2) PE20120665A1 (fr)
PL (2) PL2687202T3 (fr)
PT (2) PT2459167E (fr)
RS (2) RS52913B2 (fr)
SG (2) SG178185A1 (fr)
SI (2) SI2459167T2 (fr)
TN (1) TN2012000023A1 (fr)
TW (2) TWI474834B (fr)
UA (2) UA104254C2 (fr)
WO (1) WO2011012637A2 (fr)
ZA (2) ZA201109459B (fr)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200707078B (en) 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
DK2132573T3 (da) 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2456789A1 (fr) * 2009-07-24 2012-05-30 F. Hoffmann-La Roche AG Optimisation de la production d anticorps
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
BR112014007521A8 (pt) 2011-10-14 2018-04-10 Genentech Inc método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AR090244A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
JP6254581B2 (ja) 2012-05-18 2017-12-27 ジェネンテック， インコーポレイテッド 高濃度モノクローナル抗体製剤
LT2864346T (lt) * 2012-06-21 2019-01-25 Synthon Biopharmaceuticals B.V. Antikūnų gryninimo metodas
WO2014052713A2 (fr) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Protéines de liaison à her2 et vegf-a à stabilité améliorée
KR101454646B1 (ko) * 2012-11-05 2014-10-27 (주)한국비엠아이 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX367748B (es) * 2012-12-21 2019-09-04 Glenmark Pharmaceuticals Sa Formulación de anticuerpo anti her2.
RU2694055C2 (ru) * 2013-03-13 2019-07-09 Дженентек, Инк. Составы антител
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
KR20240042540A (ko) * 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CN104906576B (zh) * 2014-03-13 2018-06-19 四川科伦博泰生物医药股份有限公司 可供皮下注射的高浓度抗vegf抗体配制剂
EP3581586A1 (fr) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Procédés de traitement d'un cancer du sein précoce à l'aide du trastuzumab-mcc-dm1 et du pertuzumab
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
EP3193932B1 (fr) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Formulations d'anticorps
TWI721959B (zh) 2014-12-04 2021-03-21 美商健生生物科技公司 治療急性骨髓性白血病之抗ｃｄ３８抗體
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
US9824394B1 (en) 2015-02-06 2017-11-21 Square, Inc. Payment processor financing of customer purchases
US9779432B1 (en) 2015-03-31 2017-10-03 Square, Inc. Invoice financing and repayment
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
LT3302551T (lt) 2015-05-30 2024-09-10 F. Hoffmann-La Roche Ag Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
MA46315A (fr) * 2015-06-22 2019-08-07 Janssen Biotech Inc Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
WO2017003270A1 (fr) * 2015-07-02 2017-01-05 주식회사 녹십자 Agent thérapeutique et procédé de traitement de maladie de hunter
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
EP3357508A4 (fr) * 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Préparation pharmaceutique d'anticorps anti-pd-1 stable et application de celle-ci dans un médicament
RS61800B1 (sr) 2015-10-23 2021-06-30 Merus Nv Vezujući molekuli koji inhibiraju rast kancera
MA43187B1 (fr) * 2015-11-03 2021-02-26 Janssen Biotech Inc Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
EP3393494A1 (fr) 2015-12-22 2018-10-31 Novartis Ag Méthodes de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur-15 de croissance et de différenciation (gdf-15)
WO2018002181A1 (fr) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
CU24561B1 (es) 2016-06-30 2022-01-13 Celltrion Inc Formulación farmacéutica líquida estable
MX2019002967A (es) 2016-09-14 2019-07-04 Teneobio Inc Anticuerpos de union a cd3.
CA3041350A1 (fr) * 2016-11-10 2018-05-17 Translate Bio, Inc. Administration sous-cutanee d'arn messager
KR20250016462A (ko) 2016-12-21 2025-02-03 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
KR20210134432A (ko) * 2017-01-17 2021-11-09 제넨테크, 인크. 피하 her 2 항체 제형
CN110337450B (zh) 2017-03-02 2023-07-25 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
EP3618871A4 (fr) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3063324A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de proteines a haute concentration ayant une viscosite reduite
WO2018220100A1 (fr) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Voies d'administration pour des agonistes immunitaires
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
CN118146370A (zh) 2017-06-20 2024-06-07 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
EP3642628A1 (fr) * 2017-06-23 2020-04-29 Anette Weyergang Diagnostic et traitement du cancer
EP3658183A1 (fr) * 2017-07-28 2020-06-03 H. Hoffnabb-La Roche Ag Formulation d'anticorps bispécifique
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
EP3681908A1 (fr) 2017-09-13 2020-07-22 Teneobio, Inc. Anticorps à chaîne lourde se liant à des exoenzymes
AU2018334502A1 (en) 2017-09-15 2020-03-12 Amgen Inc. Process for lyophilized pharmaceutical formulation of a therapeutic protein
WO2019089832A1 (fr) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Méthodes de traitement du myélome multiple à haut risque
SI3727423T1 (sl) 2017-12-22 2024-08-30 Novartis Ag Zdravljenje metaboličnih motenj z različicami fgf21
CN107898756B (zh) * 2017-12-22 2020-11-20 东曜药业有限公司 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用
SG11202005880XA (en) 2017-12-22 2020-07-29 Teneobio Inc Heavy chain antibodies binding to cd22
KR20200144120A (ko) * 2018-04-16 2020-12-28 메르크 파텐트 게엠베하 열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제
EP3560945A1 (fr) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Procédés de purification de polypeptides utilisant des polysorbates
US12012461B2 (en) 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
WO2020017901A1 (fr) * 2018-07-19 2020-01-23 (주)셀트리온 Préparation pharmaceutique liquide stable
EP4714502A2 (fr) 2018-07-20 2026-03-25 TeneoTwo, Inc. Anticorps à chaîne lourde se liant à cd19
CN118773171B (zh) 2018-07-25 2026-03-13 阿特根公司 新型透明质酸水解酶突变体和包含其的药物组合物
JP2022500414A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
WO2020060183A1 (fr) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 Formation de liquide pour stabiliser un anticorps de trastuzumab
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN112955467A (zh) 2018-10-26 2021-06-11 特尼奥生物股份有限公司 与cd38结合的重链抗体
WO2020092546A1 (fr) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration d'une hyaluronidase et d'un anticorps anti-c5 pour le traitement d'états associés au complément
WO2020092233A1 (fr) 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. Anticorps anti-pd-1 humain et procédés d'utilisation associés
WO2020097141A1 (fr) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Formulations stables d'anticorps du récepteur de mort programmé 1 (mp-1) et leurs méthodes d'utilisation
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
CN111202845A (zh) * 2018-11-22 2020-05-29 上海医药集团股份有限公司 包含抗cd20抗体的药物配制剂及其制备方法和应用
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
CA3125197A1 (fr) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methodes de traitement du cancer a l'aide de combinaisons d'inhibiteurs de parp et de radioconjugues d'anticorps
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
SG11202110512WA (en) * 2019-03-25 2021-10-28 Alteogen Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
MX2021012205A (es) 2019-04-05 2022-02-21 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma.
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
UY38748A (es) 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
US20220249685A1 (en) 2019-06-19 2022-08-11 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
CN120842421A (zh) 2019-07-30 2025-10-28 魁尔斯弗生物治疗股份有限公司 双特异性抗LRRC15和CD3ε抗体
CN114206382B (zh) * 2019-08-07 2024-03-26 信达生物制药(苏州)有限公司 包含抗pd-1/her2双特异性抗体的制剂及其制备方法和用途
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
WO2021079337A1 (fr) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Formulation pharmaceutique d'anticorps anti-her2 et sa préparation
BR112022008172A2 (pt) * 2019-11-15 2022-07-12 Hoffmann La Roche Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
WO2021097220A1 (fr) 2019-11-15 2021-05-20 Seagen Inc. Méthodes de traitement du cancer du sein her2 positif avec du tucatinib en combinaison avec un conjugué médicament-anticorps anti-her2
WO2021096278A1 (fr) * 2019-11-15 2021-05-20 삼성바이오에피스 주식회사 Composition en phase liquide pour médicament à base d'anticorps
JP2023504748A (ja) * 2019-12-09 2023-02-06 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体製剤
CU20190104A7 (es) 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
IL293751A (en) 2019-12-18 2022-08-01 Teneofour Inc Heavy chain antibodies binding to cd38
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
AU2021232369B2 (en) * 2020-03-04 2025-06-05 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
CA3214992A1 (fr) 2020-04-29 2021-11-04 Teneobio, Inc. Anticorps a chaine lourde multispecifiques ayant des regions constantes de chaine lourde modifiees
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
CN113797161A (zh) * 2020-06-11 2021-12-17 上海宝济药业有限公司 一种重组人透明质酸酶的液体制剂及其应用
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
CN113827718A (zh) * 2020-06-24 2021-12-24 上海宝济药业有限公司 一种含有透明质酸酶的制剂及其应用
IL299376A (en) 2020-06-29 2023-02-01 Genentech Inc Fixed dose combination of pertuzumab plus transtuzumab
AU2021300179A1 (en) 2020-06-30 2023-02-02 Teneobio, Inc. Multi-specific antibodies binding to BCMA
EP4175673A1 (fr) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Conjugués d'anticorps anti-asgr1 et leurs utilisations
CN120738156A (zh) 2020-08-07 2025-10-03 阿特根公司 制备重组玻尿酸酶的方法
WO2022082005A1 (fr) 2020-10-16 2022-04-21 Qlsf Biotherapeutics, Inc. Composés de liaison multispécifiques se liant à pd-l1
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
WO2022141232A1 (fr) * 2020-12-30 2022-07-07 上海宝济药业有限公司 Formulation de hyaluronidase humaine recombinante et application associée
CN114762677A (zh) * 2020-12-30 2022-07-19 上海宝济药业有限公司 一种重组人透明质酸酶制剂及其应用
MX2023009567A (es) * 2021-02-19 2023-08-22 Inhibrx Inc Formulaciones de polipeptidos de union a dr5.
EP4298128A4 (fr) * 2021-02-23 2025-01-22 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Procédés de prévention, de soulagement ou de traitement de tumeurs
US20240226162A9 (en) 2021-02-25 2024-07-11 Teneobio, Inc. Anti-psma antibodies and car-t structures
US20240182597A1 (en) 2021-02-26 2024-06-06 Teneobio, Inc. Anti-muc1-c antibodies and car-t structures
ES2986813T3 (es) 2021-03-23 2024-11-12 King S College London Composiciones que comprenden polipéptidos de fusión NKG2D, CXCR2 y DAP10/DAP12 y métodos de uso de los mismos
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
KR20230166090A (ko) 2021-04-06 2023-12-06 테네오바이오, 인코포레이티드 항-cd19 항체 및 car-t 구조체
PE20240656A1 (es) 2021-04-16 2024-04-04 Teneobio Inc Anticuerpos anti-cd20 y estructuras car-t
WO2022271987A1 (fr) 2021-06-23 2022-12-29 TeneoFour, Inc. Anticorps anti-cd38 et leurs épitopes
WO2023004197A1 (fr) 2021-07-23 2023-01-26 Teneoten, Inc. Anticorps à chaîne lourde se liant à l'antigène de surface de l'hépatite b
WO2023019556A1 (fr) * 2021-08-20 2023-02-23 齐鲁制药有限公司 Préparation d'anticorps anti-her2 à haute concentration et son utilisation
MX2024004550A (es) 2021-10-14 2024-04-29 Teneobio Inc Proteinas de union a la mesotelina y usos de las mismas.
EP4511062A1 (fr) * 2022-04-22 2025-02-26 Eirgenix, Inc. Compositions pharmaceutiques contenant un anticorps anti-her2 pour administration sous-cutanée
WO2024026358A1 (fr) 2022-07-27 2024-02-01 Teneobio, Inc. Protéines de liaison à la mésothéline et leurs utilisations
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
AU2023356984A1 (en) 2022-10-05 2025-03-20 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
EP4389762A1 (fr) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibiteurs de l'activité de dux4 et leur utilisation en thérapie.
CN121079323A (zh) 2023-02-21 2025-12-05 特尼奥生物股份有限公司 c-Kit结合蛋白、嵌合抗原受体及其用途
EP4698281A1 (fr) 2023-04-18 2026-02-25 QLSF Biotherapeutics, Inc. Anticorps se liant à ly6g6d
WO2025158306A1 (fr) * 2024-01-25 2025-07-31 Intas Pharmaceuticals Ltd. Nouvelle formulation de phesgo à haute concentration
WO2025168089A1 (fr) * 2024-02-08 2025-08-14 上海宝济药业股份有限公司 Combinaison pharmaceutique pour administration sous-cutanée et utilisation associée
WO2025196207A1 (fr) 2024-03-20 2025-09-25 King's College London Compositions et procédés destinés à être utilisés dans la déplétion de cellules sénescentes et le traitement du vieillissement
US20250313641A1 (en) 2024-04-09 2025-10-09 Amgen Inc. Agonistic anti-il-2rbg heavy-chain antibodies
TW202544034A (zh) 2024-05-06 2025-11-16 美商榮都醫療公司 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
WO2025245354A1 (fr) * 2024-05-22 2025-11-27 Halozyme, Inc. Polythérapie avec du dupilumab et des hyaluronidases
WO2025249934A1 (fr) * 2024-05-29 2025-12-04 (주)알테오젠 Composition pharmaceutique pour injection sous-cutanée comprenant un antagoniste du récepteur de l'hormone de croissance et un support à action prolongée
WO2025264972A1 (fr) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Anticorps se liant à il -4 ralpha et anticorps se liant
WO2025264960A1 (fr) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Anticorps qui se lient à il -13 et anticorps qui se lient à ox40l

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943A (en) 1847-01-26 Harness-buckle
US533A (en) 1837-12-26 Truss for hermta
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE97498T1 (de) 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
JP2975679B2 (ja) 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
JP3208427B2 (ja) 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
BR9508409A (pt) 1994-07-21 1997-12-23 Akzo Nobel Nv Composição de peróxido transportável estável em armazenagem e uso de uma formulação de peróxido orgânico
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5573186A (en) 1995-03-20 1996-11-12 Moen Incorporated Stationary venturi diverter valve
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP2275119B1 (fr) * 1995-07-27 2013-09-25 Genentech, Inc. Formulation de protéine stabile, lyophilisée et isotonique
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN1260249C (zh) 1998-05-06 2006-06-21 基因技术股份有限公司 用离子交换层析纯化蛋白质
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
CN104383535A (zh) 2000-05-19 2015-03-04 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
AU2001277781A1 (en) 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10153197A1 (de) 2001-10-27 2003-05-08 Merck Patent Gmbh Pigment mit Metallglanz
PT1475101E (pt) 2002-02-14 2010-12-22 Chugai Pharmaceutical Co Ltd Fármacos em solução contendo anticorpos
TW555245U (en) 2003-01-29 2003-09-21 Hon Hai Prec Ind Co Ltd Cable connector assembly
KR20130135986A (ko) 2003-03-05 2013-12-11 할로자임, 아이엔씨 가용성 하이알우로니다제 당단백질 (ｓＨＡＳＥＧＰ), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1610820B2 (fr) 2003-04-04 2013-08-21 Genentech, Inc. Preparations d'anticorps et de proteines a forte concentration
MX342007B (es) 2003-05-14 2016-09-09 Immunogen Inc Composicion de farmaco conjugado.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004270113A1 (en) 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
EP1684822A2 (fr) 2003-10-24 2006-08-02 MDC Investment Holding, Inc. Seringue de melange a deux chambres et technique d'utilisation
KR101200133B1 (ko) * 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2592177A1 (fr) 2005-01-21 2006-07-27 Genentech, Inc. Dosage fixe d'anticorps anti-her
AU2006207901A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
ZA200707078B (en) 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EP1998806A1 (fr) 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Formulation d'anticorps monoclonal humain anti-igf-1r
US20090175847A1 (en) 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
JP5070993B2 (ja) 2007-08-27 2012-11-14 富士通株式会社 音処理装置、位相差補正方法及びコンピュータプログラム
CN101918579A (zh) * 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
AU2008340429C1 (en) 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR101251152B1 (ko) 2008-09-10 2013-04-05 에프. 호프만-라 로슈 아게 치료용 약물과 함께 사용하기 위한 전달 장치
US7905299B2 (en) 2008-09-18 2011-03-15 Longyear Tm, Inc. Articulation assembly for moving a drill mast
MX2011002402A (es) 2008-09-19 2011-04-05 Hoffmann La Roche Formulacion de anticuerpo novedosa.
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010279569A1 (en) 2009-08-04 2012-03-01 Genentech, Inc. Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR102116202B1 (ko) 2010-11-08 2020-05-28 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
BR112014007521A8 (pt) 2011-10-14 2018-04-10 Genentech Inc método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
KR20210134432A (ko) 2017-01-17 2021-11-09 제넨테크, 인크. 피하 her 2 항체 제형
CN110337450B (zh) 2017-03-02 2023-07-25 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
SG11202110512WA (en) 2019-03-25 2021-10-28 Alteogen Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
IL299376A (en) 2020-06-29 2023-02-01 Genentech Inc Fixed dose combination of pertuzumab plus transtuzumab
BR112023000707A2 (pt) 2020-07-14 2023-01-31 Hoffmann La Roche Ensaio de ligação para uma combinação de dose fixa, proteína, kits, composições e métodos para avaliar uma composição de dose fixa, fazer uma composição e para analisar o teor de proteína de uma combinação de dose fixa
MX2024011183A (es) 2022-03-14 2024-09-18 Genentech Inc Tratamientos conjuntos para el cancer de mama.

Also Published As

Publication number Publication date
US9968676B2 (en) 2018-05-15
EP4257150A2 (fr) 2023-10-11
CN102573789A (zh) 2012-07-11
SI2459167T1 (sl) 2013-07-31
EA201200204A1 (ru) 2012-08-30
EP2687202A1 (fr) 2014-01-22
CR20110679A (es) 2012-03-06
AU2010277657A1 (en) 2012-02-02
MY163001A (en) 2017-07-31
DK2459167T3 (da) 2013-06-03
TW201328708A (zh) 2013-07-16
LT2687202T (lt) 2023-07-10
RS52913B (sr) 2014-02-28
CY1114185T1 (el) 2016-08-31
AR108936A2 (es) 2018-10-10
ZA201109459B (en) 2013-05-29
US20210353753A1 (en) 2021-11-18
EA201400270A1 (ru) 2014-06-30
RS52913B2 (sr) 2022-05-31
TWI474834B (zh) 2015-03-01
CA2768458A1 (fr) 2011-02-03
NZ603900A (en) 2014-03-28
PE20131324A1 (es) 2013-11-04
DOP2015000255A (es) 2016-01-31
CL2013002550A1 (es) 2013-12-13
EA027553B1 (ru) 2017-08-31
US20250121059A1 (en) 2025-04-17
HK1215157A1 (zh) 2016-08-19
IN2012CN00961A (fr) 2013-05-24
PT2687202T (pt) 2023-06-15
JP2013224305A (ja) 2013-10-31
JP2013500947A (ja) 2013-01-10
FI2687202T3 (fi) 2023-06-21
IL253941A0 (en) 2017-10-31
ECSP12011643A (es) 2012-02-29
US20110044977A1 (en) 2011-02-24
JP5462944B2 (ja) 2014-04-02
EA031013B1 (ru) 2018-11-30
US20160166689A1 (en) 2016-06-16
US20260007743A1 (en) 2026-01-08
DK2687202T3 (da) 2023-07-10
WO2011012637A2 (fr) 2011-02-03
KR20120038540A (ko) 2012-04-23
RS64314B1 (sr) 2023-08-31
KR20130041374A (ko) 2013-04-24
EP4339212B1 (fr) 2025-06-25
PL2687202T3 (pl) 2023-07-24
CA2768458C (fr) 2013-12-03
IL217382A0 (en) 2012-02-29
CL2012000269A1 (es) 2012-10-12
MX2012001124A (es) 2012-03-29
TW201106973A (en) 2011-03-01
WO2011012637A4 (fr) 2011-11-03
CN113967194A (zh) 2022-01-25
EP2687202B1 (fr) 2023-05-10
SG178185A1 (en) 2012-03-29
CN105168125A (zh) 2015-12-23
EP2459167B2 (fr) 2022-03-02
CO6430421A2 (es) 2012-04-30
US20130216532A1 (en) 2013-08-22
JP5878144B2 (ja) 2016-03-08
US12427193B2 (en) 2025-09-30
EP4257150A8 (fr) 2025-08-13
WO2011012637A3 (fr) 2011-08-25
ECSP23041058A (es) 2023-07-31
HRP20130697T4 (hr) 2022-04-29
ES2413090T3 (es) 2013-07-15
HRP20130697T1 (en) 2013-09-30
US20180228895A1 (en) 2018-08-16
US20240207400A1 (en) 2024-06-27
EP4257150A3 (fr) 2023-11-01
KR101769652B1 (ko) 2017-08-18
EP4339212A2 (fr) 2024-03-20
PT2459167E (pt) 2013-06-24
SI2459167T2 (sl) 2022-05-31
US20250090660A1 (en) 2025-03-20
TN2012000023A1 (en) 2013-09-19
IL253941B (en) 2021-10-31
CN102573789B (zh) 2015-09-30
KR101413947B1 (ko) 2014-06-30
ZA201207815B (en) 2013-07-31
GT201200024A (es) 2013-10-28
TWI401089B (zh) 2013-07-11
PL2459167T3 (pl) 2013-10-31
EP2459167B1 (fr) 2013-05-15
AR077605A1 (es) 2011-09-07
BR112012002080A2 (pt) 2016-04-12
ES2413090T5 (es) 2022-05-03
DK4339212T3 (da) 2025-08-25
MY172245A (en) 2019-11-19
AU2010277657B2 (en) 2013-05-02
HUE062122T2 (hu) 2023-09-28
EP4339212A3 (fr) 2024-06-19
UA104254C2 (ru) 2014-01-10
HK1172236A1 (en) 2013-04-19
ES2948033T3 (es) 2023-08-30
SI2687202T1 (sl) 2023-07-31
NZ597190A (en) 2012-12-21
PL2459167T5 (pl) 2023-12-11
IL217382A (en) 2017-09-28
PE20120665A1 (es) 2012-06-01
UA102166C2 (ru) 2013-06-10
MX355450B (es) 2018-04-18
US9345661B2 (en) 2016-05-24
SG193146A1 (en) 2013-09-30
EP2459167A2 (fr) 2012-06-06
HRP20230462T1 (hr) 2023-07-21

Similar Documents

Publication Publication Date Title
MA33471B1 (fr) Formulation sous-cutanée d'anticorps anti-her2
MA33592B1 (fr) Formulations pharmaceutiques hautement concentrées
WO2008150479A3 (fr) Formulation de peptide stable à haute température
NZ596367A (en) Lyophilized therapeutic peptibody formulations
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA35136B1 (fr) Formulation pour un anticorps anti-a4b7
WO2010100200A3 (fr) Préparation d'anticorps lyophilisée
NZ606283A (en) Stable antibody compositions and methods for stabilizing same
WO2007019232A3 (fr) Formulations d'immunoconjugué
NZ600096A (en) Formulations of antibody
AR067011A1 (es) Formulaciones de anticuerpos
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
MX2022008949A (es) Formulacion de anticuerpos estable.
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
CR20240130A (es) Formulaciones de anticuerpos
MA53977B1 (fr) Compositions stables du sémaglutide et leurs utilisations
AR127813A1 (es) FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG
TH138064A (th) สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง
TH151334A (th) สูตรผสมเชิงเภสัชกรรมที่เข้มข้นสูง, ซึ่งเสถียรของแอนติ-CD20 แอนติบอดี (anti-CD20 antibody)